Literature DB >> 21947251

Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity.

Laura H Jacobson1, S Renee Commerford, Sarah P Gerber, Yu Alice Chen, Beatriz Dardik, Frederique Chaperon, Chad Schwartzkopf, Van Nguyen-Tran, Thomas Hollenbeck, Peter McNamara, Xiaohui He, Hong Liu, H Martin Seidel, Anne-Liese Jaton, Jesper Gromada, Sandra Teixeira.   

Abstract

Pharmacologic antagonism of cannabinoid 1 receptors (CB1 receptors) in the central nervous system (CNS) suppresses food intake, promotes weight loss, and improves the metabolic profile. Since the CB1 receptor is expressed both in the CNS and in peripheral tissues, therapeutic value may be gained with CB1 receptor inverse agonists acting on receptors in both domains. The present report examines the metabolic and CNS actions of a novel CB1 receptor inverse agonist, compound 64, a 1,5,6-trisubstituted pyrazolopyrimidinone. Compound 64 showed similar or superior binding affinity, in vitro potency, and pharmacokinetic profile compared to rimonabant. Both compounds improved the metabolic profile in diet-induced obese (DIO) rats and obese cynomolgus monkeys. Weight loss tended to be greater in compound 64-treated DIO rats compared to pair-fed counterparts, suggesting that compound 64 may have metabolic effects beyond those elicited by weight loss alone. In the CNS, reversal of agonist-induced hypothermia and hypolocomotion indicated that compound 64 possessed an antagonist activity in vivo. Dosed alone, compound 64 suppressed extinction of conditioned freezing (10 mg/kg) and rapid eye movement (REM) sleep (30 mg/kg), consistent with previous reports for rimonabant, although for REM sleep, compound 64 was greater than threefold less potent than for metabolic effects. Together, these data suggested that (1) impairment of extinction learning and REM sleep suppression are classic, centrally mediated responses to CB1 receptor inverse agonists, and (2) some separation may be achievable between central and peripheral effects with brain-penetrating CB1 receptor inverse agonists while maintaining metabolic efficacy. Furthermore, chronic treatment with compound 64 contributes to evidence that peripheral CB1 receptor blockade may yield beneficial outcomes that exceed those elicited by weight loss alone.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21947251     DOI: 10.1007/s00210-011-0686-y

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  45 in total

1.  SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset.

Authors:  J Simiand; M Keane; P E Keane; P Soubrié
Journal:  Behav Pharmacol       Date:  1998-03       Impact factor: 2.293

2.  REM sleep deprivation affects extinction of cued but not contextual fear conditioning.

Authors:  Amy J Silvestri
Journal:  Physiol Behav       Date:  2005-03-16

3.  The wake-promoting peptide orexin-B inhibits glutamatergic transmission to dorsal raphe nucleus serotonin neurons through retrograde endocannabinoid signaling.

Authors:  Samir Haj-Dahmane; Roh-Yu Shen
Journal:  J Neurosci       Date:  2005-01-26       Impact factor: 6.167

Review 4.  The endocannabinoid system: emotion, learning and addiction.

Authors:  Fabrício A Moreira; Beat Lutz
Journal:  Addict Biol       Date:  2008-04-16       Impact factor: 4.280

5.  Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis.

Authors:  V Santucci; J J Storme; P Soubrié; G Le Fur
Journal:  Life Sci       Date:  1996       Impact factor: 5.037

Review 6.  Effects of method, duration, and sleep stage on rebounds from sleep deprivation in the rat.

Authors:  A Rechtschaffen; B M Bergmann; M A Gilliland; K Bauer
Journal:  Sleep       Date:  1999-02-01       Impact factor: 5.849

7.  The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis.

Authors:  Daniela Cota; Giovanni Marsicano; Matthias Tschöp; Yvonne Grübler; Cornelia Flachskamm; Mirjam Schubert; Dorothee Auer; Alexander Yassouridis; Christa Thöne-Reineke; Sylvia Ortmann; Federica Tomassoni; Cristina Cervino; Enzo Nisoli; Astrid C E Linthorst; Renato Pasquali; Beat Lutz; Günter K Stalla; Uberto Pagotto
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

8.  CB1 cannabinoid receptors modulate kinase and phosphatase activity during extinction of conditioned fear in mice.

Authors:  Astrid Cannich; Carsten T Wotjak; Kornelia Kamprath; Heike Hermann; Beat Lutz; Giovanni Marsicano
Journal:  Learn Mem       Date:  2004 Sep-Oct       Impact factor: 2.460

9.  Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.

Authors:  Luc F Van Gaal; André J Scheen; Aila M Rissanen; Stephan Rössner; Corinne Hanotin; Olivier Ziegler
Journal:  Eur Heart J       Date:  2008-04-15       Impact factor: 29.983

Review 10.  Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis.

Authors:  David R Janero; Alexandros Makriyannis
Journal:  Expert Opin Emerg Drugs       Date:  2009-03       Impact factor: 4.191

View more
  5 in total

1.  Sex differences in mouse models of fear inhibition: Fear extinction, safety learning, and fear-safety discrimination.

Authors:  Jacob W Clark; Sean P A Drummond; Daniel Hoyer; Laura H Jacobson
Journal:  Br J Pharmacol       Date:  2019-04-15       Impact factor: 8.739

2.  Effects of CB1 receptor blockade on monosodium glutamate induced hypometabolic and hypothalamic obesity in rats.

Authors:  Wei Chen; Zhenhua Chen; Nina Xue; Zhibing Zheng; Song Li; Lili Wang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-26       Impact factor: 3.000

3.  Interrelationship of CB1R and OBR pathways in regulation of metabolic, neuroendocrine, and behavioral responses to food restriction and voluntary wheel running.

Authors:  Abdoulaye Diane; Donna F Vine; James C Russell; C Donald Heth; W David Pierce; Spencer D Proctor
Journal:  J Appl Physiol (1985)       Date:  2014-06-05

4.  Modulation of food consumption and sleep-wake cycle in mice by the neutral CB1 antagonist ABD459.

Authors:  Anushka V Goonawardena; Andrea Plano; Lianne Robinson; Ruth Ross; Iain Greig; Roger G Pertwee; Robert E Hampson; Bettina Platt; Gernot Riedel
Journal:  Behav Pharmacol       Date:  2015-04       Impact factor: 2.293

5.  Endocannabinoid Signaling Regulates Sleep Stability.

Authors:  Matthew J Pava; Alexandros Makriyannis; David M Lovinger
Journal:  PLoS One       Date:  2016-03-31       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.